Gastrointestinal cancer
VBC108-01-01
Phase 1/2a open-label clinical trial evaluating VBC108, a CLDN18.2 and CDH17-directed bi-specific antibody drug conjugate, in participants with advanced malignant gastrointestinal tumors.
Trial overview
Clinical Area
Medical Oncology
Disease
Gastric
Disease site
Gastrointestinal (GI)
Study Phase
I
Trial Identifiers
Registration number: NCT07700160
Principal Investigator(s)
··
··